Ramucirumab (RAM) for sorafenib intolerant patients with hepatocellular carcinoma (HCC) and elevated baseline alpha fetoprotein (AFP): Outcomes from two randomized phase 3 studies (REACH, REACH2).

Affiliation auteurs!!!! Error affiliation !!!!
TitreRamucirumab (RAM) for sorafenib intolerant patients with hepatocellular carcinoma (HCC) and elevated baseline alpha fetoprotein (AFP): Outcomes from two randomized phase 3 studies (REACH, REACH2).
Type de publicationJournal Article
Year of Publication2019
AuteursLlovet JM, Yen C-J, Finn RS, Kang Y-K, Kudo M, Galle PR, Assenat E, Pracht M, Lim HYeong, Rau K-M, Borg C, Hiriart J-B, Daniele B, Berg T, Chung HCheol, Godinot N, Wang C, Hsu Y, Schelman WR, Zhu AX
JournalJOURNAL OF CLINICAL ONCOLOGY
Volume37
Date PublishedMAY 20
Type of ArticleMeeting Abstract
ISSN0732-183X
DOI10.1200/JCO.2019.37.15_suppl.4073